Argos Therapeutics Inc. (NASDAQ:ARGS) shares traded down 3.5% on Wednesday . The company traded as low as $5.95 and last traded at $6.12, with a volume of 60,032 shares changing hands. The stock had previously closed at $6.34.

A number of research analysts recently weighed in on the company. Zacks Investment Research cut Argos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. Needham & Company LLC reiterated a “buy” rating on shares of Argos Therapeutics in a report on Saturday, April 23rd. FBR & Co reiterated a “buy” rating on shares of Argos Therapeutics in a report on Saturday, March 19th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $11.00 target price on shares of Argos Therapeutics in a report on Monday, June 20th. Finally, Roth Capital lifted their target price on Argos Therapeutics from $11.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, April 19th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Argos Therapeutics has an average rating of “Buy” and an average target price of $11.84.

The company’s 50-day moving average is $6.13 and its 200-day moving average is $5.34. The company’s market cap is $156.90 million.

Argos Therapeutics (NASDAQ:ARGS) last posted its quarterly earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by $0.01. On average, equities research analysts anticipate that Argos Therapeutics Inc. will post ($1.74) EPS for the current fiscal year.

Argos Therapeutics, Inc (Argos) is a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s advanced product candidate is AGS-003, which the Company is developing for the treatment of metastatic renal cell carcinoma (mRCC) and other cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.